SCHEMBL23970772

SCHEMBL23970772

C=Cc1ccnc(OC)c1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 4/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LMNA P02545 1/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA12 O43570 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KDM4C Q9H3R0 2/20 0.33
KDM6B O15054 1/20 0.33
KDM5C P41229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23970776 0.81 ALDH1A1 (0.36) KDM4EMAPK1NPSR1ALDH1A1MTNR1A
SCHEMBL7042463 0.78 CA12 (0.57) TDP1POLBKDM4ECA1CA2
SCHEMBL27775349 0.76 KDM4E (0.34) KDM4ELMNAALDH1A1L3MBTL1KDM4C
SCHEMBL28521418 0.76 KDM4E (0.46) KDM4ENPSR1LMNAALDH1A1KMT2A
SCHEMBL27032969 0.76 POLB (0.43) TDP1POLBKDM4EMAPK1LMNA
SCHEMBL12794738 0.76 POLB (0.43) TDP1POLBKDM4EMAPK1LMNA
SCHEMBL30639556 0.76 POLB (0.43) TDP1POLBKDM4EMAPK1LMNA
SCHEMBL25270407 0.75 FDPS (0.43) KDM4ELMNACA1CA2CA12
SCHEMBL23970774 0.75 ALDH1A1 (0.53) TDP1POLBKDM4ELMNACA1
SCHEMBL22090396 0.75 TDP1 (0.42) TDP1POLBKDM4ELMNACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES PADI4, PADI2, PADI1 TDP1 199/4885POLB 866/4885KDM4E 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.